Research Centers of Excellence | Lewy Body Dementia Association LBDA

Research Centers of Excellence

 

LBDA Research Centers of Excellence span a growing, nationwide network of top scientific facilities working to defeat LBD.

LBDA Research Centers of Excellence

See how some of the nation’s leading research and clinical care institutions are joining the LBDA in the fight against LBD.

Learn More >

Clinical Trials

Help advance LBD research. Opportunities to participate are on the rise across the country. Find a study near you.

Learn More >

Research

Stay up-to-date on research news. Read our easy-to-understand summaries on important LBD research, as well as articles that highlight cutting-edge advances in diagnosis and clinical care.

Learn More >

Participate in Research

Learn about the different types of clinical research being conducted and find tools to help you decide if a clinical trial may be right for you.

Learn More >

ACADIA Pharmaceuticals Submits ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA
ACADIA Pharmaceuticals has applied to the FDA for a new indication for their drug, Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis.

New Research Definition of Mild Cognitive Impairment with Lewy Bodies (MCI-LB)
A global panel of experts in dementia with Lewy bodies (DLB) has published the first formal research criteria to aid in the study of the mild cognitive impairment (MCI) stage of DLB. The article also includes descriptions of two other “prodromal” (early) presentations of DLB: delirium-onset DLB and psychiatric- onset DLB.

Alzheimer’s and Lewy Bodies: When Two Pathologies Collide
A new study suggests a cardiac imaging scan may help differentiate ‘pure’ Alzheimer’s disease and Alzheimer’s disease (AD) with co-existing dementia with Lewy bodies (DLB). The ability to identify these “AD+DLB” cases is an important step forward for the study of potential new treatments, as people with AD+DLB may respond differently to medications.

Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD
A recent study out of the Netherlands assessed how the ‘mild cognitive impairment’ stage of LBD progresses to dementia, revealing an early predictor of progression. The study also suggests caregivers were negatively impacted by the disease even in the very early stage.

Biogen’s Aducanumab Clinical Trial Results Revealed
Why are we sharing information about an Alzheimer’s study? Because most people with LBD also have some changes in the brain similar to Alzheimer’s disease.

Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis
In December, ACADIA Pharmaceuticals, presented its top-line results from its Phase 3 HARMONY study. This was a clinical trial of a drug, pimavanserin, in people with dementia with recent hallucinations or delusions, including some people with LBD.

LBDA Scientific Outreach in 2019
The last few months of 2019 have been busy for LBDA. We've been working tirelessly to raise awareness and promote national discussion on Lewy body dementias. Learn about what we've been up to in this article.

LBD Caregiver Experience Differs between Spouses and Adult Children
Being a dementia caregiver can negatively affect a person’s psychological well-being. But what’s known about the impact of LBD caregiving? And how it might differ based on who is providing the care? Newly published data from this project reveals some unique needs between spousal and adult child LBD caregivers. The project was led by James Galvin, MD of Florida Atlantic University. Dr. Galvin is a member of LBDA’s Scientific Advisory Council and leads of 1 of LBDA’s 25 LBDA Research Centers of Excellence.

Updated LBD Research Recommendations Published
Every 3 years, a national research summit is held to update research strategies for non-Alzheimer’s dementias. This 2-day national event is one of 3 rotating annual summits held in response to the federal government’s national plan to address Alzheimer’s disease and related dementias. Read the recommendations on advancing LBD research and improving dementia terminology from the 2019 summit, two key priorities for LBDA.

National Institutes of Health Award $14 million for LBD Research
People who have LBD plus changes in the brain associated with Alzheimer’s disease tend to have more aggressive disease progression. However, science has not yet explained why these two disease processes seem to have a synergistic effect.

Rate of Dementia Diagnosis Varies by Clinician Type and Patient Race/Ethnicity
A dementia diagnosis is an essential step to access to treatment, resources and services. But little is known about how most people are diagnosed, or how the diagnosis changes over time. A new study analyzed Medicare claims data to reveal the diagnosing physician types, how diagnosis changes over time, and how race, ethnicity and gender impact who receives a dementia diagnosis.

 

 

 

All Research Funding Announcements
Stay up-to-date on LBD-relevant funding opportunity announcements from federal agencies like the National Institutes of Health and Department of Defense.

 

 

19th Brain Health Forum | Distinguishing the Different Dementias - Cancelled
Tuesday, April 21, 2020
Creek Orthodox Cathedral
The Ballroom at the Carlos Center
2500 Clairmont Road
Atlanta, GA 30329